Updated on: November 28, 2022
This BCCDC Clinical Practice Guide is updated as follows: Recommendation language for monoclonal antibodies, including tixagevimab/cilgavimab, Impacts of waning, second boosters, hybrid immunity and bivalent vaccines and more.
Information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the information.